Hypothesis

Age‑associated NAD+ decline reduces ATP‑dependent CK2 activity, which preferentially hinders the nuclear import of ERK1 relative to ERK2 because ERK1’s slower intrinsic shuttling kinetics make it more dependent on efficient NLS phosphorylation. This creates an ERK1‑cytoplasmic/ERK2‑nuclear signaling imbalance that promotes a senescent transcriptional program.

Mechanistic Basis

• ERK1/2 nuclear entry requires dual phosphorylation and importin7‑mediated transport, a process driven by CK2 phosphorylation of the Ser‑244/Pro‑245/Ser‑246 nuclear translocation sequence[1]
• ERK1 contains a 20‑aa insert N‑terminal to the poly‑alanine region that slows its nuclear accumulation compared with ERK2[2]
• CK2 is an ATP‑dependent kinase; its activity falls when cellular ATP declines[1]
• NAD+ depletion during aging elevates CD38 and PARP1 activity, consuming NAD+ and indirectly limiting ATP production via impaired oxidative phosphorylation[5]
• Low ATP therefore reduces CK2‑mediated NLS phosphorylation, disproportionately affecting the slower‑importing ERK1 isoform
• Persistent cytoplasmic ERK1 sustains MAPK feedback loops where oxidative stress inhibits phosphatases, maintaining ERK signaling[3]
• Simultaneously, NAD+ scarcity curtails the energetically costly SASP, suggesting a coordinated metabolic downregulation rather than random damage[4]

Testable Predictions

1. In aged or NAD+‑depleted cells, the nuclear/cytoplasmic ratio of ERK1 will be significantly lower than that of ERK2, while total ERK1/2 levels remain unchanged
2. Pharmacological elevation of NAD+ (NR, NMN) or CK2 activation will restore ERK1 nuclear import without altering ERK2 dynamics
3. Expressing a phosphomimetic ERK1 NLS (S244E/S245E/S246E) will rescue nuclear localization of ERK1 in low‑NAD+ conditions and reduce senescence markers (SA‑β‑gal, p16^INK4a^)
4. Conversely, inhibiting CK2 in young cells will mimic the aged ERK1/2 localization pattern and induce premature senescence even when NAD+ is abundant

Experimental Approach

• Cell models: Primary human fibroblasts and iPSC‑derived mesenchymal cells cultured at early (passage 5) and late (passage 20) passages; parallel treatment with NAD+ precursors or CD38 inhibitor (78c)
• Readouts:
  • Subcellular fractionation followed by Western blot for ERK1 and ERK2; quantify nuclear/cytoplasmic ratios
  • Live‑cell imaging of ERK1‑ERK2 GFP‑fusion proteins to measure import rates (FRAP/FLIP)
  • CK2 activity assay (phosphorylation of a peptide substrate) correlated with ATP levels (luciferase‑based)
  • Senescence assessment: SA‑β‑gal staining, p16/p21 qPCR, SASP cytokine ELISA
  • Rescue experiments: overexpress WT or phosphomimetic ERK1 NLS constructs; assess localization and senescence
• Controls: ERK2‑specific NLS mutant, non‑targeting siRNA, and CK2‑inactive kinase‑dead mutant

Expected Outcome

If NAD+ decline selectively limits ERK1 nuclear entry via CK2‑ATP dependence, restoring NAD+ or CK2 activity will correct ERK1 localization and attenuate senescence‑associated phenotypes. Failure to observe isoform‑specific changes would falsify the hypothesis and suggest that ERK1/2 shuttling is uniformly regulated or that other NAD+‑sensitive pathways dominate the senescence phenotype.